FrancophonIA/ELRC3.0 huggingface dataset:
English: This is a summary of the European public assessment report (EPAR) for Exforge HCT.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Exforge HCT.
English: It is available as tablets containing amlodipine, valsartan and hydrochlorothiazide in the following amounts: 5/160/12.5 mg, 10/160/12.5 mg, 5/160/25 mg, 10/160/25 mg and 10/320/25 mg.
Slovenian: Na voljo je v obliki tablet, ki vsebujejo amlodipin, valsartan in hidroklorotiazid v naslednjih količinah: 5/160/12,5 mg, 10/160/12,5 mg, 5/160/25 mg, 10/160/25 mg in 10/320/25 mg.
English: For more information about treatment with Exforge HCT, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Exforge HCT preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Valsartan is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a body hormone called angiotensin II.
Slovenian: Valsartan je antagonist receptorja za angiotenzin II, kar pomeni, da zavira delovanje telesnega hormona, imenovanega angiotenzin II.
English: Exforge HCT is taken by mouth as one tablet once a day, at the same time of the day and preferably in the morning.
Slovenian: Zdravilo Exforge HCT se jemlje peroralno, in sicer se zaužije ena tableta enkrat na dan ob isti uri, če je le mogoče, zjutraj.
English: The CHMP therefore decided that Exforge HCT's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: CHMP je zaključil, da so koristi zdravila Exforge HCT večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
English: The combination of the three active substances has an additive effect, reducing the blood pressure more than the individual medicines alone.
Slovenian: Kombinacija treh zdravilnih učinkovin ima aditiven učinek, saj zniža krvni tlak bolj kot vsako posamezno zdravilo posebej.
English: The main study showed the benefit of the highest strength of Exforge HCT in lowering the blood pressure.
Slovenian: Glavna študija je pokazala koristnost uporabe največjega odmerka zdravila Exforge HCT pri zniževanju krvnega tlaka.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Exforge HCT.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Exforge HCT, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Amlodipine is a ‘calcium channel blocker'.
Slovenian: Amlodipin je zaviralec kalcijevih kanalčkov.
English: The three active substances in Exforge HCT are anti-hypertensive medicines that are already in use in the European Union (EU).
Slovenian: Tri zdravilne učinkovine v zdravilu Exforge HCT so zdravila proti zvišanemu krvnemu tlaku, ki se že uporabljajo v Evropski uniji (EU).
English: Exforge HCT is used to treat essential hypertension (high blood pressure) in adults whose blood pressure is already adequately controlled with a combination of amlodipine, valsartan and hydrochlorothiazide.
Slovenian: Zdravilo Exforge HCT se uporablja za zdravljenje esencialne hipertenzije (visokega krvnega tlaka) pri odraslih, pri katerih je krvni tlak že ustrezno uravnan z uporabo kombinacije amlodipina, valsartana in hidroklorotiazida.
English: The most common side effects with Exforge HCT (seen in between 1 and 10 patients in 100) are hypokalaemia (low blood potassium levels), dizziness, headache, hypotension (low blood pressure), dyspepsia (heartburn), pollakiuria (abnormally frequent urination), fatigue (tiredness) and oedema (fluid retention).
Slovenian: Najpogostejši neželeni učinki zdravila Exforge HCT (opaženi pri 1 do 10 bolnikih od 100) so hipokaliemija (nizka raven kalija v krvi), omotica, glavobol, hipotenzija (nizek krvni tlak), dispepsija (zgaga), polakisurija (neobičajno pogosto uriniranje), utrujenost in edem (zadrževanje tekočine).
English: Exforge HCT is a medicine that contains three active substances, amlodipine, valsartan and hydrochlorothiazide.
Slovenian: Exforge HCT je zdravilo, ki vsebuje tri zdravilne učinkovine amlodipin, valsartan in hidroklorotiazid.
English: The average reduction in blood pressure was around 39.7/24.7 mmHg in patients taking Exforge HCT compared with 32/19.7 mmHg, 33.5/21.5 mmHg and 31.5/19.5 mmHg in patients taking valsartan/hydrochlorothiazide, valsartan/amlodipine and hydrochlorothiazide/amlodipine combinations, respectively.
Slovenian: Povprečno znižanje krvnega tlaka je bilo okrog 39,7/24,7 mmHg pri bolnikih, ki so prejemali zdravilo Exforge HCT, v primerjavi z 32/19,7 mmHg pri bolnikih, ki so prejemali kombinacije valsartan/hidroklorotiazid, 33,5/21,5 mmHg pri bolnikih, ki so prejemali kombinacije valsartan/amlodipin, in 31,5/19,5 mmHg pri bolnikih, ki so prejemali kombinacije hidroklorotiazid/amlodipin.
English: For all doses, Exforge HCT also met requirements to prove that it was comparable to the combinations of the individual active substances taken seperately.
Slovenian: Pri vseh odmerkih je zdravilo Exforge HCT izpolnilo tudi zahteve, s katerimi je bilo dokazano, da je primerljivo s kombinacijami posameznih zdravilnih učinkovin, vzetih ločeno.
English: The daily dose of Exforge HCT should not exceed 10 mg of amlodipine, 320 mg of valsartan and 25 mg of hydrochlorothiazide.
Slovenian: Dnevni odmerek učinkovin zdravila Exforge HCT ne sme biti večji od 10 mg amlodipina, 320 mg valsartana in 25 mg hidroklorotiazida.
English: What benefit has Exforge HCT shown during the studies?
Slovenian: Kakšne koristi je zdravilo Exforge HCT izkazalo med študijami?
English: Treatment with the highest strength of Exforge HCT was more effective at treating hypertension than dual combinations containing any of the two active substances.
Slovenian: Zdravljenje z največjim odmerkom zdravila Exforge HCT je bilo pri zdravljenju hipertenzije učinkovitejše od zdravljenja z dvojnimi kombinacijami, ki so vsebovale po dve zdravilni učinkovini.
English: For the full list of all side effects reported with Exforge HCT, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Exforge HCT, glejte navodilo za uporabo.
English: The dose of Exforge HCT to be used is the same as the doses of three individual active substances that the patient was taking before.
Slovenian: Odmerek učinkovin zdravila Exforge HCT mora biti enak odmerkom treh posameznih zdravilnih učinkovin, ki jih je bolnik prejemal pred tem.
English: By blocking the receptors to which angiotensin II normally attaches, valsartan stops the hormone having an effect, allowing the blood vessels to widen and blood pressure to reduce.
Slovenian: Ker valsartan ustavi njegovo delovanje z zaviranjem receptorjev, na katere se angiotenzin II običajno veže, hormonu prepreči učinkovanje, zaradi česar se krvne žile lahko razširijo, krvni tlak pa zniža.
English: It works by increasing urine output, reducing the volume of fluid in the blood and lowering the blood pressure.
Slovenian: Deluje tako, da poveča izločanje seča, zaradi česar se zmanjša količina tekočine v telesu in zniža krvni tlak.
English: Exforge HCT must not be used in people who are hypersensitive (allergic) to the active substances, to other sulfonamides, to dihydropyridine derivatives or to any of the other ingredients in Exforge HCT.
Slovenian: Zdravila Exforge HCT ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) zdravilne učinkovine, druge sulfonamide, derivate dihidropiridina ali katero koli drugo sestavino zdravila
English: By reducing the flow of calcium into the cells, amlodipine prevents the cells from contracting and helps the blood vessel walls to relax and widen, thereby reducing blood pressure.
Slovenian: Amlodipin z zmanjšanjem pretoka kalcija v celice prepreči njihovo krčenje in pomaga pri sproščanju in širjenju sten žil ter tako znižuje krvni tlak.
English: Other information about Exforge HCT
Slovenian: Druge informacije o zdravilu Exforge HCT
English: Exforge HCT must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension) in patients with type 2 diabetes or in patients with moderate or severe kidney impairment.
Slovenian: Prav tako se ne sme uporabljati v kombinaciji z zdravili, ki vsebujejo aliskiren (ki se uporablja za zdravljenje esencialne hipertenzije), pri bolnikih s sladkorno boleznijo tipa 2 ali zmerno do hudo ledvično okvaro.
English: Finally, Exforge HCT must not be used in patients with hypokalaemia (low blood potassium levels), hyponatraemia (low blood sodium levels) and hypercalcaemia (high blood calcium levels) that do not respond to treatment and in patients with hyperuricaemia (high blood levels of uric acid) that causes symptoms.
Slovenian: Zdravila Exforge HCT poleg tega ne smejo uporabljati bolniki s hipokaliemijo (nizko ravnjo kalija v krvi), hiponatriemijo (nizko ravnjo natrija v krvi) in hiperkalciemijo (visoko ravnjo kalcija v krvi), ki se ne odzivajo na zdravljenje, ter bolniki s simptomatsko hiperurikemijo (visoko koncentracijo sečne kisline v krvi).
English: What is the risk associated with Exforge HCT?
Slovenian: Kakšna tveganja so povezana z zdravilom Exforge HCT?
English: It must also not be used in patients who have liver or bile problems (such as jaundice), severe kidney problems, anuria (a condition in which a patient cannot make or pass urine) or in patients undergoing dialysis (a blood clearance technique).
Slovenian: Zdravila prav tako ne smejo uporabljati osebe, ki imajo obolenja jeter ali žolčnika (kot je npr. zlatenica), hude ledvične okvare, anurijo (nezmožnost izločanja urina) ali bolniki na dializi (tehniki čiščenja krvi).
English: In addition, one main study was carried out in 2,271 patients with moderate to severe hypertension with the highest strength of Exforge HCT (320 mg valsartan, 10 mg amlodipine and 25 mg hydrochlorothiazide).
Slovenian: Poleg tega je bila izvedena glavna študija, v kateri so proučevali 2 271 bolnikov z zmerno do hudo hipertenzijo, ki so prejemali največji odmerek zdravila Exforge HCT (320 mg valsartana, 10 mg amlodipina in 25 mg hidroklorotiazida) Bolniki so osem tednov prejemali bodisi zdravilo Exforge HCT bodisi eno od treh kombinacij, ki so vsebovale le dve zdravilni učinkovini.
English: Why has Exforge HCT been approved?
Slovenian: Zakaj je bilo zdravilo Exforge HCT odobreno?
English: The CHMP noted that patients already taking the three active substances would be more likely to comply with their treatment if prescribed Exforge HCT which combines the three substances in a single tablet.
Slovenian: CHMP je menil, da bi uporaba zdravila Exforge HCT, pri katerem so tri zdravilne učinkovine prisotne v eni tableti, bolnikom, ki tri zdravilne učinkovine že prejemajo ločeno, omogočila doslednejše jemanje zdravila.
English: How has Exforge HCT been studied?
Slovenian: Kako je bilo zdravilo Exforge HCT raziskano?
English: How is Exforge HCT used?
Slovenian: Kako se zdravilo Exforge HCT uporablja?
English: What is Exforge HCT?
Slovenian: Kaj je zdravilo Exforge HCT?
English: What is Exforge HCT used for?
Slovenian: Za kaj se zdravilo Exforge HCT uporablja?
English: It is a hybrid medicine.
Slovenian: Je „hibridno zdravilo“.
English: The tablets are taken in 2 to 4 divided doses.
Slovenian: Tablete se jemljejo razdeljene v od 2 do 4 odmerke.
English: In adults, the total recommended daily dose is from 3 to 6.5 tablets, and in children from 1.5 to 4 tablets.
Slovenian: Pri odraslih je skupni priporočeni dnevni odmerek od 3 do 6,5 tablet, pri otrocih pa od 1,5 do 4 tablete.
English: What measures are being taken to ensure the safe and effective use of Cuprior?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Cuprior?
English: Cuprior is available as 150 mg tablets.
Slovenian: Zdravilo Cuprior je na voljo v obliki tablet po 150 mg.
English: Cuprior trientine
Slovenian: Cuprior trientin
English: This means that it is similar to a ‘reference medicine' (in this case Trientine Dihydrochloride 300 mg capsules) also containing trientine.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“ (v tem primeru zdravilu trientinijev dihidroklorid v obliki 300-miligramskih kapsul), ki tudi vsebuje trientin.
English: The company provided data from the published literature, which show that trientine significantly increases copper elimination in the urine.
Slovenian: Družba je predložila podatke iz objavljene literature, ki kažejo, da trientin bistveno poveča izločanje bakra v urinu.
English: Other information about Cuprior
Slovenian: Druge informacije o zdravilu Cuprior
English: The CHMP noted that trientine has been used for over 30 years to treat patients with Wilson's disease.
Slovenian: Odbor CHMP je upošteval, da se trientin pri zdravljenju bolnikov z Wilsonovo boleznijo uporablja več kot 30 let.
English: What are the benefits and risks of Cuprior?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Cuprior?
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Cuprior's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Cuprior večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: This is a summary of the European public assessment report (EPAR) for Cuprior.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Cuprior.
English: The difference between Cuprior and the reference medicine is that Cuprior contains another form of trientine (trientine tetrahydrochloride) and does not need to be stored in a refrigerator.
Slovenian: Razlika med zdravilom Cuprior in referenčnim zdravilom je, da Cuprior vsebuje drugo vrsto trientina (trientinijev tetrahidroklorid) in ga ni treba shranjevati v hladilniku.
English: Cuprior should be taken on an empty stomach, at least one hour before or two hours after meals.
Slovenian: Zdravilo Cuprior je treba vzeti na tešče vsaj eno uro pred obrokom ali dve uri po njem.
English: The full EPAR for Cuprior can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Cuprior je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Since Cuprior is a hybrid medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Cuprior hibridno zdravilo, se njegove koristi in tveganja štejejo za enake kot pri referenčnem zdravilu.
English: It is not intended to provide practical advice on how to use Cuprior.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: Doses are adjusted according to patient response and levels of copper in the body.
Slovenian: Odmerki se prilagajajo glede na bolnikov odziv in ravni bakra v telesu.
English: It works by attaching to copper in the body and forming a complex that is then eliminated in the urine.
Slovenian: Deluje tako, da se veže na baker v telesu in tvori kompleks, ki se nato izloči z urinom.
English: Cuprior is used in patients who cannot take D-penicillamine, another medicine for this condition.
Slovenian: Zdravilo Cuprior se uporablja pri bolnikih, ki ne smejo jemati D-penicilamina, drugega zdravila za to bolezen.
English: Cuprior is a medicine used to treat patients aged 5 years and older with Wilson's disease, a genetic condition in which copper absorbed from food builds up in the body, particularly in the liver and the brain, causing damage.
Slovenian: Zdravilo Cuprior se uporablja za zdravljenje bolnikov, starih 5 let in več, ki imajo Wilsonovo bolezen, genetsko motnjo, pri kateri se baker iz hrane nalaga v telesu, še posebej v jetrih in možganih, kjer povzroča okvare.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Cuprior have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Cuprior upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: Although Cuprior releases more trientine in the body than the reference medicine, this difference can be addressed by lowering the dose, which is in any case adjusted according to patient response and levels of copper in the body.
Slovenian: Čeprav zdravilo Cuprior sprosti v telo več trientina kot referenčno zdravilo, je mogoče to razliko upoštevati z zmanjšanjem odmerka, ki je v vsakem primeru prilagojen odzivu bolnika in ravnem bakra v telesu.
English: The company also carried out a study to compare the levels of trientine in the blood after having taken Cuprior with those for the reference medicine.
Slovenian: Družba je izvedla tudi študijo za primerjavo ravni trientina v krvi po jemanju zdravila Cuprior s tistimi pri referenčnem zdravilu.
English: For more information about treatment with Cuprior, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Cuprior preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Results showed that Cuprior produces higher levels of the active substance in the blood than the reference medicine.
Slovenian: Rezultati so pokazali, da zdravilo Cuprior proizvede višje ravni zdravilne učinkovine v krvi kot referenčno zdravilo.
English: Why is Cuprior approved?
Slovenian: Zakaj je bilo zdravilo Cuprior odobreno?
English: For practical information about using Cuprior, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Cuprior naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Cuprior can only be obtained with a prescription and treatment should be started by a specialist with experience in the management of Wilson's disease.
Slovenian: Predpisovanje in izdaja zdravila Cuprior je le na recept, zdravljenje pa mora uvesti zdravnik specialist, ki ima izkušnje z zdravljenjem Wilsonove bolezni.
English: What is Cuprior and what is it used for?
Slovenian: Kaj je zdravilo Cuprior in za kaj se uporablja?
English: To take account of this difference, Cuprior is used at lower doses.
Slovenian: Ta razlika je upoštevana tako, da so odmerki zdravila Cuprior manjši.
English: Cuprior contains the active substance trientine.
Slovenian: Zdravilo Cuprior vsebuje zdravilno učinkovino trientin.
English: The active substance in Cuprior, trientine, is a chelating agent.
Slovenian: Zdravilna učinkovina zdravila Cuprior, trientin, je kelator.
English: How has Cuprior been studied?
Slovenian: Kako je bilo zdravilo Cuprior raziskano?
English: How is Cuprior used?
Slovenian: Kako se zdravilo Cuprior uporablja?
English: How does Cuprior work?
Slovenian: Kako zdravilo Cuprior deluje?
English: The Member States should ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented:
Slovenian: Države članice morajo zagotoviti, da so vsi spodaj opisanih pogoji ali omejitve v zvezi z varno in učinkovito uporabo zdravila izpolnjeni:
English: CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
Slovenian: POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH IZPOLNIJO DRŽAVE ČLANICE
English: The Marketing Authorisation Holder (MAH) shall agree the details of a controlled distribution system for the 20 ml vial of Revatio 0.8 mg/ml solution for injection with the National Competent Authorities and must implement such programme nationally to ensure that prior to prescribing all health care professionals who intend to prescribe and/or dispense Revatio 0.8 mg/ml solution for injection are provided the following: - Information for Healthcare professionals - Copy of the Summary of Product Characteristics (SPC) - Data Capture Form (DCF) designed to facilitate reporting of events of hypotension and associated problems
Slovenian: Takšen program mora izvesti nacionalno, da bodo pred predpisovanjem zdravila vsi zdravstveni delavci, ki nameravajo predpisovati in/ali izdajati Revatio 0,8 mg/ml raztopina za injiciranje dobili: - Informacije za zdravstveno osebje - Izvod povzetka glavnih značilnosti zdravila (SmPC) - Obrazec za zajem podatkov (angl. Data Capture Form - DCF) za lažje poročanja o hipotenziji in povezanih težavah
English: The Information for Healthcare professionals should contain the following key elements: - Information about the Pharmacovigilance Monitoring Programme regarding the potential risk of clinically relevant hypotension and related problems to be put into place with the use of the DCF.
Slovenian: Informacije za zdravstveno osebje morajo vključevati naslednje ključne elemente: - informacije o programu farmakovigilančnega nadzora v zvezi možnimi tveganji klinično pomembne hipotenzije in povezanih težav, ki jih je treba evidentirati z obrazcem za zajem podatkov (DCF) - informacije o prehodu s 50-ml viale na 20-ml vialo Revatio 0,8 mg/ml raztopina za injiciranje.
English: The Marketing Authorisation Holder shall agree the information for healthcare professionals, and the healthcare professionals to be targeted, with the national competent authority of each Member State prior to the launch of the 20 ml vial of Revatio 0.8 mg/ml solution for injection in that country.
Slovenian: Imetnik dovoljenja za promet (MAH) bo podrobnosti sistema nadzorovane distribucije za 20-ml viale zdravila Revatio 0,8 mg/ml raztopina za injiciranje uskladil s pristojnimi nacionalnimi organi.
English: Undesirable effects
Slovenian: Neželeni učinki
English: If necessary, <Product name> can be used during pregnancy.
Slovenian: Zdravilo <ime zdravila> se po potrebi lahko uporablja med nosečnostjo.
English: Adopted at the 12-15 March 2019 PRAC
Slovenian: Sprejeto na seji odbora PRAC med 12. in 15. marcem 2019
English: Conventional studies using the currently accepted standards for the evaluation of toxicity to reproduction and development are not available.
Slovenian: Običajne študije z uporabo trenutno sprejetih standardov vrednotenja toksičnosti za razmnoževanje in razvoj niso na voljo.
English: What you need to know before you use [product name]
Slovenian: Kaj morate vedeti, preden boste uporabili zdravilo [ime zdravila]
English: If clinically needed, paracetamol can be used during pregnancy however it should be used at the lowest effective dose for the shortest possible time and at the lowest possible frequency.
Slovenian: Če je klinično potrebno, se paracetamol lahko uporablja med nosečnostjo, vendar v čim manjšem še učinkovitem odmerku, čim krajši čas in z najmanjšo možno pogostnostjo.
English: Hypoparathyroidismh
Slovenian: Hipoparatiroidizemh
English: Epidemiological studies on neurodevelopment in children exposed to paracetamol in utero show inconclusive results.
Slovenian: Epidemiološke študije o razvoju živčevja pri otrocih, izpostavljenih paracetamolu in utero, kažejo nejasne rezultate.
English: • Decreased function of the parathyroid gland
Slovenian: • Zmanjšano delovanje obščitnične žleze
English: Paracetamol - Paracetamol use in pregnancy and child neurodevelopment and effects on the urogenital apparatus (EPITT no 17796)
Slovenian: Paracetamol - uporaba paracetamola med nosečnostjo in razvoj živčevja pri otroku ter učinki na urogenitalni aparat (št. EPITT 17796)